AktieBiotechnologie

Apellis Pharmaceuticals

WKN
A2JAAW
Ticker
APLS
1JK
ISIN
US03753U1060
46,050 USD
+1,860 USD+4,21 %
Geld
41,150 USD
(300 Stk.)
Brief
47,010 USD
(100 Stk.)

Unternehmens­daten

Apellis Pharmaceuticals

Unternehmenstermine

07
Mai
Geschäftsbericht
Ergebnisberichte & Dividenden

Stammdaten zu Apellis Pharmaceuticals

WKN
A2JAAW
ISIN
US03753U1060
Home-Symbol
APLS
Symbol
1JK
Branche
Biotechnologie
Sektor
Chemie / Pharma / Gesundheit
Unternehmen
APELLIS PHARMACEUTICALS
Land

Marktdaten

Marktkapitalisierung
5,18 Mrd. EUR
Anzahl Aktien
120,58 Mio. Stk.
Streubesitz
16,74 %

Alle Aktien des Unternehmens APELLIS PHARMACEUTICALS

Mitglieder & Anteilseigner

Anteilseigner

StreubesitzWellington Management Co. LLPMorningside Group Ltd.EcoR1 Capital, LLCAvoro Capital Advisor LLCThe Vanguard Group, Inc.T. Rowe Price Investment Management, Inc.BlackRock Fund AdvisorsJennison Associates LLCSSgA Funds Management, Inc.Octagon Capital Advisors LPMorgan Stanley & Co. LLCT. Rowe Price Associates, Inc. (Investment Management)Assenagon Asset Management SA (Germany)Fidelity Management & Research Co. LLCCedric FrancoisBoxer Capital LLCJPMorgan Investment Management, Inc.Geode Capital Management LLCInvus Public Equities Advisors LLCPictet Asset Management SA
  • Streubesitz (16,74 %)
  • Wellington Management Co. LLP (13,64 %)
  • Morningside Group Ltd. (10,62 %)
  • EcoR1 Capital, LLC (9,27 %)
  • Avoro Capital Advisor LLC (9,21 %)
  • The Vanguard Group, Inc. (7,81 %)
  • T. Rowe Price Investment Management, Inc. (5,23 %)
  • BlackRock Fund Advisors (4,01 %)
  • Jennison Associates LLC (2,72 %)
  • SSgA Funds Management, Inc. (2,42 %)
  • Octagon Capital Advisors LP (2,33 %)
  • Morgan Stanley & Co. LLC (2,32 %)
  • T. Rowe Price Associates, Inc. (Investment Management) (1,99 %)
  • Assenagon Asset Management SA (Germany) (1,78 %)
  • Fidelity Management & Research Co. LLC (1,74 %)
  • Cedric Francois (1,69 %)
  • Boxer Capital LLC (1,43 %)
  • JPMorgan Investment Management, Inc. (1,42 %)
  • Geode Capital Management LLC (1,35 %)
  • Invus Public Equities Advisors LLC (1,18 %)
  • Pictet Asset Management SA (1,12 %)

Kontakt

Apellis Pharmaceuticals Inc

Bilanz von APELLIS PHARMACEUTICALS

Gewinn & Verlust von APELLIS PHARMACEUTICALS